Koning Goes Live on Investment Platform, Republic, With More Milestones to Come
FOR IMMEDIATE RELEASE: AUG 11, 2021
Koning’s Series C fundraise is now available to both accredited and everyday investors via two leading tech investment websites.
Atlanta, GA: After launching on Revere on Monday, Koning Corporation has launched a second fundraising campaign on the investment platform Republic. “We’re very excited to be both on Republic and Revere. This is our official first public solicitation offering – a huge milestone for the company,” says Koning’s US CEO, Lutao Ning.
“After working through the worst of the pandemic in 2020, we’re re-energized and ready to bring no-compression breast exams to women everywhere.”
Koning Milestones
Breast CT received dedicated reimbursement codes in the US in March and clinics running exams with the Koning Breast CT (KBCT) have been billing to those codes with great success. The next generation of the KBCT is nearing completion and will begin deploying into hospitals globally Q4 2021. Clinics around the world are seeing the power of Breast CT through our published clinical results, papers, and clinical conferences. These can be seen on our relaunched website: www.koninghealth.com.
Koning’s series C fundraise will continue the global expansion of the company, allowing more women to receive suitable exams. The company will use future funds to finance market growth for the current products in China and US, and to develop a smaller, lower cost device, covering a more expansive screening market.
About Koning: Koning is a global HealthTech company that focuses on improving the breast imaging industry with its patented Koning Breast CT (KBCT). Koning’s vision is to create a revolution in medical imaging through advanced computed tomography technology and dramatically improve the way clinicians visualize and evaluate breast tissue. The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide.